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Abstract 
Background: Acute myeloid leukemia (AML) cells can be induced to undergo terminal differentiation with subse-
quent loss of tumorigenicity using 1,25-dihydroxyvitamin D3 (1,25D) alone or in combination with hematopoietic 
cytokines. KG1 cells are resistant to 1,25D-induced cell differentiation. These cells have the aberrant signal transduc-
tion resulting from a constitutively active fusion protein FOP2-FGFR1, a constitutively active STAT1 and a high level of 
interferon (IFN) stimulated genes (ISGs).
Methods: In this paper we report that in KG1 cells with constitutively activated protein FOP2-FGFR1 delivery of plas-
mid DNA disrupted FOP2-FGFR1 fusion gene.
Results: As a consequence, STAT1 signal transduction pathway became switched off, the expression of vitamin D 
receptor (VDR) gene was increased and sensitivity to 1,25D-induced differentiation was restored. The activation of 
ISGs in KG1 cells resulted in resistance to externally added IFNs, and also this effect was reversed in cells with dis-
rupted FOP2-FGFR1 fusion gene.
Discussion: In this paper we have documented for the first time a link between constitutively active STAT1 signal 
transduction pathway, high level of ISGs and low expression of VDR gene.
Conclusions: We show in this paper that delivery of plasmid DNA to the cells may disrupt fusion gene FOP2-FGFR1 
which occurs in a disease entity called 8p11 myeloproliferative syndrome. Inhibition of the FOP2-FGFR1 signal trans-
duction pathway restored sensitivity of the cells to 1,25D-induced cell differentiation.
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Background
Chromosomal translocations are characteristic features 
of lymphoma and leukemia. A number of malignan-
cies are driven by chromosomal translocations which 
involve the gene for fibroblast growth factor receptor 1 
(FGFR1) and fuse it to the distant aminoterminal part-
ners. In blood cells, these translocations are associated 
with the disease entity called 8p11 myeloproliferative 
syndrome, which rapidly transforms to acute myeloid 
leukemia (AML) [1]. The only available cell line model for 
this disease is the KG1 cell line, where FGFR1 oncogene 
partner 2 (FOP2)–FGFR1 fusion gene was identified, 
which results in the generation of a constitutively active 
fusion protein FOP2–FGFR1 [2]. KG1 cells have been 
Open Access
Cell & Bioscience
*Correspondence:  ema@cs.uni.wroc.pl 
Laboratory of Protein Biochemistry, Faculty of Biotechnology, University 
of Wroclaw, Joliot-Curie 14a, 50-383 Wroclaw, Poland
Page 2 of 13Marchwicka et al. Cell Biosci  (2016) 6:7 
characterized by a constitutive activation of signal trans-
ducer and activator of transcription (STAT) 5 [2] and 
STAT1 [3]. Under physiological conditions interferons 
(IFNs) activate STAT signal transduction pathways, lead-
ing to transcription of IFN-stimulated genes (ISGs) [4]. 
This is the basic immune mechanism which controls the 
spread of viral infections. OAS proteins which activate 
degradation of viral RNA by 2′,5′-oligoadenylate-depend-
ent ribonuclease L (RNAse L) are among ISGs [5, 6]. 
Other ISGs include the one that encodes protein MX1, 
which inhibits the replication cycle of influenza virus [7]. 
G1P2 encodes a ubiquitin-like protein which binds to tar-
get proteins in response to IFNα or IFNβ stimulation and 
has chemotactic activity of neutrophils [8], while IFIT1 
gene encodes a protein which may inhibit viral replica-
tion and translational initiation [9].
AML is characterized by the accumulation of primi-
tive hematopoietic blast cells, which lose their ability of 
normal differentiation [10]. AML cells can be induced to 
undergo terminal differentiation with subsequent loss of 
tumorigenicity. However, at present the clinical success 
of differentiation therapy for AML is limited to one rare 
subtype, which can be cured using all-trans retinoic acid 
(ATRA) [11]. There is a need to develop differentiation 
therapies to other subtypes, for example, using 1,25-dihy-
droxyvitamin D3 (1,25D) alone or in combination with 
hematopoietic cytokines or phytonutrients [12]. KG1 
cells have been reported to be resistant to 1,25D-induced 
differentiation [13], and our earlier experiments revealed 
that this was caused by a very low expression level of 
vitamin D receptor (VDR) gene and protein [14]. There 
are hundreds of VDR-controlled genes, many of them 
responsible for maintaining the calcium-phosphate 
homeostasis [15], however, there are also many involved 
in blood cell functions, exemplified by CD14, a mac-
rophage co-receptor for bacterial LPS [16]. VDR is not 
essential for blood cells development, but is important 
for their proper function [17, 18], thus low VDR level 
and low VDR activity in leukemic cells may contribute to 
their malignant phenotype.
In this study we have addressed the possible reasons 
of KG1 cells’ resistance to 1,25D-induced differentia-
tion. In our search for the role of interactions between 
various nuclear receptors, we wanted to generate geneti-
cally modified KG1 subline with retinoic acid receptor α 
(RARA) gene silenced. Using electroporation DNA deliv-
ery method we have obtained two sublines: KG1-CtrA 
(transfected with a plasmid containing scrambled DNA 
sequence) and KG1-RARA (transfected with the plasmid 
coding short hairpin (sh) RNA against RARA gene). In 
both transfected cell lines VDR gene and protein expres-
sion levels increased and 1,25D-resistance was reversed, 
however this was not due to the gene silencing. We have 
therefore addressed the molecular events that have led to 
the reversal of 1,25D resistance. We found that the high 
level of FOP2–FGFR1 and ISGs transcription, constitu-
tively present in KG1 cells, were suppressed in KG1-CtrA 
and KG1-RARA cells. Similarly, constitutive activity of 
STAT1 in KG1 cells, was not longer present in transfected 
cells. In contrast, in KG1-CtrA and KG1-RARA cells the 
expression and activity of VDR were much higher than 
in KG1 cells. The high activation of ISGs in KG1 cells 
resulted in resistance to externally added IFNs, and also 
this effect was reversed in transfected cells. The low level 
of VDR expression in KG1 cells wasn’t caused by the 
repressed transcription, but at least in part by degrada-
tion of VDR mRNA. Addition of curcumin, an inhibitor 
of RNAse L, to KG1 cells partly restored 1,25D-induced 
cell differentiation.
Results
Differentiation of KG1, HL60, KG1‑CtrA and KG1‑RARA
There are many AML cell lines available, which have 
variable susceptibilities to 1,25D-induced differentiation 
[19]. Usually the cell differentiation is tested by meas-
uring levels of CD11b and CD14 cell surface proteins. 
CD11b is a cell adhesion molecule present mostly on the 
surface of granulocytes and monocytes [20], while CD14 
is a co-receptor for bacterial lipopolysaccharide charac-
teristic for monocytes and macrophages [21]. HL60 cell 
line responded to 1,25D with upregulation of CD11b 
and CD14 cell differentiation markers, while KG1 cells 
were unresponsive [14]. In a search of molecular rea-
sons we decided to transfect KG1 cells with plasmids 
which encode shRNA against RARA. In order to prop-
erly validate our experiment we also transfected the cells 
with a control plasmid (CtrA), which codes scrambled 
sequence of shRNA. This way we obtained KG1-CtrA 
and KG1-RARA sublines of KG1 cells. Then the wild-
type and transfected cells were exposed to 1,25D for 96 h 
and tested for cell differentiation markers in flow cytom-
etry. HL60 cells which are sensitive to 1,25D moderately 
increased the expression of CD11b (Fig. 1a), and strongly 
increased CD14 (Fig.  1b). In KG1 cells the cell surface 
markers remained at the control levels, while KG1-CtrA 
cells increased the expression of CD14 similarly to HL60 
cells. In KG1-RARA cells exposed to 1,25D the expres-
sion of CD14 was comparable to KG1-CtrA cells. It 
should be noted that when HL60 cells were transfected 
with CtrA plasmid, their 1,25D-induced differentia-
tion was similar to that of wild type HL60 cells [22], and 
when KG1 cells were transformed using lentiviral vector 
encoding scrambled shRNA they remained resistant to 
1,25D (KG1-Ctr-len cells in Fig. 1a, b).
In order to validate whether the expression of RARA 
gene was indeed efficiently knocked down in KG1-RARA 
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cells, the RARα mRNA (Fig.  1c) and protein levels 
(Fig.  1d) were compared in KG1-CtrA and KG1-RARA 
cells. The mRNA expression was reduced to approxi-
mately 40 % of initial level, and was followed by reduced 
RARα protein content in the nuclei of KG1-RARA cells.
The plasmids that were used in our experiments confer 
the resistance to puromycin, an antibiotic which is toxic 
to eukaryotic cells. Transfected KG1 cells were selected 
from untransfected in the culture using this antibiotic. 
Since puromycin inhibits protein translation, it seemed 
unlikely that the effect of 1,25D-induced differentiation 
was caused by the exposure of the cells to puromycin. 
However, in order to verify that, we cultured KG1 cells 
at sub-lethal concentrations of puromycin (250 nM) and 
exposed them to 10 nM 1,25D and we detected that KG1 
still did not differentiate (not shown). These experiments 
confirmed that cell differentiation of KG1-CtrA and 
KG1-RARA cells wasn’t caused by puromycin.
VDR in HL60, KG1, KG1‑CtrA and KG1‑RARA
In order to test whether the susceptibility of KG1-CtrA 
and KG1-RARA cells to 1,25D-induced differentiation 
was mediated by VDR, we tested the levels of this pro-
tein in our cells. It has been documented that VDR in 
AML cells accumulates in the cell nuclei in response to 
1,25D exposure [23, 24]. In KG1 cells the VDR expression 
level is low, but it increases after addition of ATRA [14]. 
Therefore, for the next experiments we exposed KG1, 
HL60, KG1-CtrA and KG1-RARA cells to 10 nM 1,25D, 
500 nM ATRA or both for 72 h and then detected VDR 
in the cell cytosol, nucleosol and chromatin fractions. As 
presented in Fig.  2a, the level of VDR protein is low in 
all untreated cells, but in HL60, KG1-CtrA and in KG1-
RARA it grows substantially after exposure to 1,25D, and 
does not change after ATRA. In KG1 cells the situation is 
different. In these cells 1,25D does not change the level of 
VDR considerably, ATRA causes a slight increase of VDR 
Fig. 1 Differentiation of AML cell lines in response to 1,25D. KG1, HL60, KG1-CtrA, KG1-RARA and KG1-Ctr-len cells were exposed to 1,25D (10 or 
100 nM) for 96 h and then the expression of CD11b (a) and CD14 (b) differentiation markers was detected using flow cytometry. The experiments 
were repeated 3–4 times and the mean percentages of positive cells (±SEM) are presented in Y-axis. The samples that differ significantly from the 
control are marked with asterisk (p < 0.05). To verify RARA gene silencing in KG1-RARA cells, the expression levels of RARA mRNA (c) in KG1-CtrA 
and KG1-RARA cell lines were measured by Real-time PCR relative to GAPDH expression levels. The bar charts show mean values (±SEM) of relative 
quantity (RQ). The levels of RARα protein were determined in the cytosol and nuclei of KG1, KG1-CtrA and KG1-RARA cells by western blots (d). The 
cytosolic (C) and nuclear (N) extracts were separated by SDS-PAGE, transferred to PVDF membranes and the proteins were revealed using anti-RARα, 
anti-actin and anti-HDAC antibodies
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levels, but ATRA and 1,25D when added at the same time 
cause significant accumulation of VDR in nucleosol and 
in chromatin fractions. The above results show that the 
regulation of VDR protein level after delivery of plasmid 
DNA changed from the mode typical for 1,25D-resistant 
KG1 cells to the mode typical for 1,25D-sensitive HL60 
cells. To test whether the differences in VDR protein 
levels between wild type KG1 cells and the transfected 
sublines come from protein translation, or from pro-
tein stability, the levels of VDR mRNA were detected in 
these cells, and compared to HL60 cells. As presented in 
Fig.  2b the constitutive expression level of VDR mRNA 
Fig. 2 Expression of VDR gene and regulation of VDR and protein in AML cell lines in response to 1,25D and ATRA. KG1, HL60, KG1-CtrA and KG1-
RARA cells were exposed to 10 nM 1,25D or to 500 nM ATRA or both for 72 h and then expression of VDR protein was studied (a). The cells were 
fractionated into cytosolic, nucleosolic and chromatin-bound fractions. Fractionated proteins were analyzed in western blots using anti-VDR, anti-
actin and anti-Histone antibodies. The experiments were repeated from 2 (HL60) to 5 (KG1) times and representative blots are presented. C control, 
D 10 nM 1,25D; A 500 nM ATRA. The constitutive expression levels of VDR mRNA (b) in the above cell lines were measured by Real-time PCR relative 
to GAPDH expression levels. The bar charts show mean values of three experiments (±SEM) of relative quantity (RQ)
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in KG1-CtrA was about 4 times higher than in HL60 
cells and about 57 times higher than in KG1 cells, while 
in KG1-RARA cells it was about 2.4 times higher than in 
HL60 cells and about 35 times higher than in KG1 cells.
VDR mRNA in HL60, KG1 and KG1‑CtrA and its regulation 
in response to ATRA
In our previous work we demonstrated that in HL60 and 
in KG1 cells VDR mRNA was regulated in an opposite 
manner in response to ATRA; in HL60 cells it was down-
regulated, while in KG-1 it was up-regulated [14]. Thus, 
we addressed the question whether the genetic modi-
fication of KG1-CtrA and KG1-RARA cells influenced 
the regulation of VDR mRNA in response to ATRA. 
Thus HL60 (Fig.  3a), KG1 (Fig.  3b) KG1-CtrA (Fig.  3c) 
and KG1-RARA (Fig. 3d) cells were for 24, 48 and 96 h 
exposed to 1  μM ATRA and the expression of VDR 
mRNA was measured using Real-time PCR versus the 
expression of GAPDH which is stable in all these cell lines. 
The experiment showed that expression of VDR mRNA 
in KG1-CtrA and KG1-RARA cells was down-regulated 
by ATRA, similarly to HL60 cells, but unlikely wild-type 
KG1 cells. The fact that ATRA regulates the expression 
of the VDR gene in bone and mammary cells has been 
described in the past, but the mechanism of this regula-
tion is not well understood [25, 26]. It should be noticed 
that ATRA is a non-selective ligand of the three distinct 
isoforms of retinoic acid receptors (RAR) α, β and γ, 
which occur in numerous splicing variants [27] and these 
isoforms may differentially contribute to the regulation of 
VDR gene expression.
Chromatin accessibility assay in HL60, KG1 and KG1‑CtrA
We next addressed the question whether increased 
expression of VDR after delivery of plasmid DNA to KG1 
cells was caused by epigenetic effects. Thus we tested if 
there is a difference in chromatin accessibility within 
these cell lines as accessibility strongly correlates with 
gene expression. Using the EpiQ analysis kit, the chro-
matin state was identified based on how accessible the 
DNA was to nucleases. We evaluated the accessibility of 
the VDR promoter region in HL60, KG1 and KG1-CtrA 
Fig. 3 Regulation of VDR gene in response to ATRA in AML cell lines. KG1 (a), HL60 (b), KG1-CtrA (c) and KG1-RARA (d) cells were exposed to 1 µM 
ATRA for 24, 48 and 96 h and then expression of VDR gene was measured by Real-time PCR relative to GAPDH expression levels. The bar charts show 
mean values of three experiments (±SEM) of relative quantity (RQ). Values that differ significantly (p < 0.05) from those obtained for control cells are 
marked with asterisks
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cells. In all cell lines the proximal region of the VDR 
gene showed a low degree of accessibility (in a rage of 
20–65  %), which according to the test manufacturer, is 
considered moderately silenced when compared to that 
of GAPDH, an epigenetically “open” gene (Fig.  4). The 
accessibility of VDR was therefore identified as being in 
similar range of silencing in all three cell lines.
FGFR1‑FOP signaling in KG1, KG1‑CtrA and KG1‑RARA cells
In further search for a molecular mechanism of the 
restored susceptibility to 1,25D in transfected KG1 sub-
lines, we addressed the oncogene which drives malig-
nant transformation in KG1 cells. KG1 cells have been 
reported to express the wild-type FGFR1, wild-type 
FOP2 and the fusion FOP2–FGFR1 gene and protein [2]. 
Thus we tested the levels of mRNA for FOP2–FGFR1 
fusion gene, FOP2 and FGFR1 in KG1, KG1-CtrA and 
KG1-RARA cells, normalized to GAPDH expression lev-
els using Real-time PCR. We observed that the expres-
sion of the fusion FOP2–FGFR1 gene which is high in 
KG1, was undetectable in KG1-CtrA and KG1-RARA 
cells (Fig. 5a). Next, the question of fusion gene integrity 
in transfected cells was addressed. The whole sequence 
of the fusion FOP2–FGFR1 gene is not available, but the 
region between exon 4 of FOP2 and exon 10 of FGFR1 
has been studied. This region contained the elements 
from intron 4–5 of FOP2, the inverted and truncated 
exon 9, and intron 9–10 of FGFR1 [28]. We decided to 
amplify the above region from the genomic DNA isolated 
from wild-type KG1 cells as well as from KG1-CtrA and 
KG1-RARA cells. As presented in Fig.  5b, in KG1 and 
in KG1-Ctr-len cells the expected product of about 5 kb 
pairs was present, while in KG1-CtrA and KG1-RARA 
cells it was absent, showing that transfection with plas-
mid DNA disrupted the fusion gene integrity.
As it has been presented in the past, there is a constitu-
tive activation of STAT1 transcription factor in KG1 cells 
[3]. In our experiments we tested, if this transcription 
factor is also constitutively active in KG1-CtrA and KG1-
RARA cells. We tested the presence of Tyr-701 phos-
pho-STAT1 in these cells, relative to the total amount of 
STAT1 and to the actin content. The results presented 
in Fig. 5c document constitutive activation of STAT1 in 
KG1 cells, but neither in KG1-CtrA nor in KG1-RARA 
cells. However, not only the levels of phosphorylated 
STAT1 were higher in wild type, than in transfected cells. 
The total amount of STAT1 was also higher in KG1 than 
in both transfected sublines, when compared to the actin 
content.
IFN stimulated genes in HL60, KG1, KG1‑CtrA 
and KG1‑RARA cells
Since STAT1 was constitutively active in KG1 cells, but 
no longer in KG1-CtrA and KG1-RARA cells, we were 
interested in downstream events in these cell lines. Tran-
scription factors from STAT family are activated predom-
inantly by IFNs, so we decided to test ISGs expression. 
For that purpose we used commercially available IFNr 
qRT-Primers kit, which allows to quantify the expression 
of five well characterized ISGs, which we tested in HL60, 
KG1, KG1-CtrA and KG1-RARA cells. As presented in 
Fig. 6 expression levels of OAS1, MX1, G1P2 and IFIT1 
were significantly higher in KG1 cells than in KG1-CtrA, 
KG1-RARA and HL60. The only ISG tested, which wasn’t 
upregulated in KG1 cells was IFNB gene (not shown). It is 
noteworthy, that in normal cells signal transduction from 
IFNs causes not only phosphorylation and activation of 
STAT1 transcription factor, but also upregulates STAT1 
gene expression [29]. This is why STAT1 is in some pub-
lications included into the group of ISGs [30]. Therefore, 
high STAT1 protein content in KG1 cells (presented in 
Fig. 5b) most probably might be attributed to the consti-
tutive activation of IFN signaling in these cells.
Differentiation of KG1, KG1‑CtrA and KG1‑RARA cells 
after externally added IFNs
As it has been reported in the past, IFNα and IFNγ aug-
ment the differentiation of leukemic cells induced by 
other factors [31]. For example, it has been shown that 
blast cells from patients with chronic myeloid leukemia 
when cultured with IFNα and granulocyte–macrophage 
colony stimulating factor, developed a morphology char-
acteristic for dendritic cells [32]. Since KG1 cells, where 
Fig. 4 Accessibility of VDR and GAPDH proximal promoters in HL60, 
KG1 and KG1-CtrA. HL60, KG1 and KG1-CtrA cells were treated with 
nucleases in order to stimulate chromatin digestion after which 
chromatin was isolated, followed by Real-time PCR. The difference in 
CT values between digested and undigested chromatin allowed for 
evaluation of chromatin states (% chromatin accessibility) among the 
cell lines. GAPDH was used as the control (constitutively expressed) 
and RHO was used as the reference (epigenetically silenced) gene. 
Data are the mean values (±SEM) of three individual experiments
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INF-like signaling was constitutively switched on, did 
not resemble antigen presenting cells, we have addressed 
the question what would be the effect of externally added 
IFNs. We have tested various concentrations of IFNα and 
IFNγ, and we found that 10  ng/ml dose was the high-
est, that did not cause toxicity after 96 h exposure time. 
KG1, KG1-CtrA and KG1-RARA cells were thus treated 
with IFNα or IFNγ with or without 10 nM 1,25D for 96 h, 
and then the expression of CD11b and CD14 cell sur-
face markers was tested in flow cytometry. As presented 
in Fig. 7, there was no effect of IFNs towards KG1 cells, 
where expression of CD11b and CD14 was similar to the 
control values in all treated samples. On the contrary, in 
KG1-CtrA and in KG1-RARA cells, IFNγ was able to sig-
nificantly increase levels of CD11b and CD14 molecules 
at the cell surface and it acted in an additive manner with 
1,25D.
Differentiation of KG1 after externally added curcumin
RNAse L is a latent enzyme, expressed in nearly every 
mammalian cell type. In its latent state it is inhibited by 
an intrinsic Ribonuclease L Inhibitor and it is activated 
in response to IFNs. The only external and cell permeable 
RNAse L inhibitor documented until now is curcumin, 
which in  vitro inhibits the enzyme activity at 5–10  µM 
concentrations [33]. Therefore, we decided to test, if 
the addition of curcumin would restore 1,25D-induced 
differentiation in wild type KG1 cells. It appeared that 
10  µM curcumin itself is quite efficient differentiation-
inducing factor in KG1 cells, however, the differentiation 
is limited to CD14 cell surface marker with no increase 
in CD11b. Curcumin and 1,25D added simultaneously to 
KG1 cells produced a synergistic effect of CD14 expres-
sion (Fig. 8). This suggests that in part the resistance of 
KG1 cells to 1,25D was caused by RNAse L activation.
Fig. 5 Expression of FOP2–FGFR1 and presence of phospho-STAT1 in KG1, KG1-CtrA and KG1-RARA cells. The expression of wild-type FGFR1, wild-
type FOP2 and the fusion FOP2–FGFR1 gene in KG1, KG1-CtrA and KG1-RARA cells was tested by Real-time PCR relative to GAPDH expression levels 
(a). The expression levels obtained for KG1 cells were calculated as 1. The bar charts show mean values of three experiments (±SEM) of relative 
quantity (RQ). Values that differ significantly (p < 0.05) from those obtained for KG1 cells are marked with asterisks. The region between exon 4 of 
FOP2 and exon 10 of FGFR1 within the fusion FOP2–FGFR1 gene was amplified from genomic DNA obtained from KG1, KG1-CtrA, KG1-RARA and 
KG1-Ctr-len cells (b). The PCR products were separated in 1 % agarose gel and visualized with ethidium bromide under UV light. Total cell lysates 
from KG1, KG1-CtrA and KG1-RARA cells were analyzed in western blots for the presence of active STAT1 and total STAT1 level (c). Actin content 
was tested as a control of equal loading and transfer of proteins. The experiment was repeated two times, each in duplicate, and illustrative blot is 
presented
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Discussion
Delivery of DNA into cancer cells in  vitro and in  vivo 
has become a standard protocol worldwide. It has been 
believed that delivery of control plasmid DNA has no 
significant effect to the cells, however some data were 
published which show that this is not always the truth. It 
has been shown that in some tumor cell lines delivery of 
control plasmid DNA caused significant increase in the 
expression of following ISGs: IRF7, STAT1, MIG, MICA 
and ITGAL [30]. The phenomenon of activation of IFN 
signaling in transfected cells was attributed predomi-
nantly to delivery of short interfering (si) RNAs to the 
cells [34]. In this paper we show that plasmid DNA deliv-
ered to acute myeloid leukemia cells may integrate into 
genomic DNA and disrupt FOP2–FGFR1 fusion gene. 
Our results show that this “side effect” of DNA delivery 
might have positive influence towards cell phenotype.
The above phenomenon has encouraged us to address 
the question of low VDR expression level in KG1 cells. 
Disruption of FOP2–FGFR1 fusion gene unexpect-
edly restored sensitivity of KG1 cells to 1,25D. This was 
caused by increased levels of VDR mRNA, followed by 
translation of VDR protein. VDR protein in genetically 
modified KG1-CtrA and KG1-RARA cells was transcrip-
tionally functional and these cells resembled 1,25D-sen-
sitive HL60 cells. In transfected KG1 sublines 1,25D 
induced expression of CD14 cell surface marker, which 
is a characteristic feature of mature monocytes and nec-
essary for phagocytosis [35]. Moreover, the regulation of 
VDR expression by ATRA, which in KG1 cells is opposite 
from that in HL60 cells, showed to be identical in both 
HL60, KG1-CtrA and KG1-RARA cells. We then hypoth-
esized that the transcription of VDR gene was silenced in 
KG1 cells in comparison with KG1-CtrA or HL60 cells. 
Since the epigenetic mechanisms of gene silencing are 
variable, we took advantage of EPIQ chromatin analysis 
test. The results of this test show the accessibility of chro-
matin in the promoter region of studied gene, regard-
less the epigenetic modifications. These results showed 
that promoter region of VDR has a moderate degree of 
accessibility within all HL60, KG1 and KG1-CtrA cell 
lines, thus epigenetic gene silencing was not the reason 
Fig. 6 Expression of ISGs in AML cell lines. Transcription levels of MX1 (a), IFIT1 (b), G1P2 (c) and OAS1 (d) were measured in HL60, KG1, KG1-CtrA 
and KG1-RARA cells by Real-time PCR relative to GAPDH expression levels. The expression levels obtained for HL60 cells were calculated as 1. The 
bar charts show mean values of three experiments (±SEM) of relative quantity (RQ). Values that differ significantly (p < 0.01) from those obtained for 
HL60 cells are marked with asterisks, while the values that differ significantly (p < 0.02) from those obtained for KG1 cells are marked by hash
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of various VDR expression levels in HL60, KG1 and KG1-
CtrA cells.
Subsequently, we looked at the aberrant signal trans-
duction in KG1 cells. It was reported before that tran-
scription factor STAT1 is constitutively active in KG1 [3]. 
Indeed, we have found high levels of STAT1 protein, and 
its constitutive activation in KG1 cells, but not longer in 
KG1-CtrA and in KG1-RARA cells. In response to dis-
ruption of FOP2–FGFR1, STAT1 signal transduction 
became switched off, which pointed out that constitu-
tively active fusion FOP2–FGFR1 kinase is an upstream 
activator of this pathway.
Among the ISG genes constitutively activated in KG1 
cells were the ones that code for OAS proteins, which in 
Fig. 7 Differentiation of KG1, KG1-CtrA and KG1-RARA cells in response to IFNs and 1,25D. KG1, KG1-CtrA and KG1-RARA cells were exposed to 
10 ng/ml of IFNα, 10 ng/ml of IFNγ with or without 10 nM 1,25D for 96 h and then the expression of CD11b and CD14 differentiation markers was 
detected using flow cytometry. Experiments were repeated 3 (KG1 and KG1-RARA) or 4 (KG1-CtrA) times. The bar charts show the density of CD11b 
and CD14 antigens on the cell surface, expressed as mean channel of fluorescence (MCF) values (±SEM). Values that differ significantly (p < 0.05) 
from those obtained for 1,25D treated cells are marked with asterisks, while the values that differ significantly (p < 0.01) from those obtained for 
IFNγ-treated cells are marked by hash
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turn activate RNase L, highly regulated, latent endori-
bonuclease [36]. Since OAS genes were overexpressed in 
KG1, but neither in HL60, KG1-CtrA nor in KG1-RARA 
cells, the degradation of mRNA could be one of the rea-
sons of VDR low level. In order to verify whether RNAse 
L activation contributes to the resistance of KG1 cells to 
1,25D, we used curcumin, which has been reported as the 
only cell permeable RNAse L inhibitor. Our experiments 
revealed, that curcumin itself is a differentiation-inducing 
factor towards KG1 cells, and in combination with 1,25D 
it had synergistic pro-differentiation effect. It should be 
noted however, that degradation of VDR RNA may in 
part contribute to resistance of KG1 cells to 1,25D, but it 
is not the only reason.
Conclusions
In summary, we show in this paper that delivery of 
plasmid DNA to the cells may disrupt fusion gene 
Fig. 8 Differentiation of KG1 cells in response to curcumin and 1,25D. KG1 cells were exposed to 10 µM curcumin with or without 1,25D (10 or 
100 nM) for 96 h and then the expression of CD11b and CD14 differentiation markers was detected using flow cytometry. Addition of 1,25D at 
both concentrations significantly enhanced the expression of CD14 in KG1 cells when compared to curcumin-treated cells. The experiments were 
repeated 5 times and illustrative dot-blots are presented in a, while the mean percentages of positive cells (±SEM) are presented in b. The samples 
that differ significantly from the curcumin-treated cells are marked with asterisk (p < 0.02)
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FOP2–FGFR1 which occurs in a disease entity called 
8p11 myeloproliferative syndrome. Whether this is lim-
ited to the cell line or present also in blast cells from 
patients needs to be studied in future, even though this 
disease is very rare. More importantly, inhibition of the 
FOP2–FGFR1 signal transduction pathway restored sen-
sitivity of the cells with fusion kinase to 1,25D-induced 
cell differentiation. We suppose that this finding needs 




HL60 cells were a from a local cell bank at the Institute 
of Immunology and Experimental Therapy in Wroclaw 
(Poland), while KG1 cells were purchased from the Ger-
man Resource Center for Biological Material (DSMZ 
GmbH, Braunschweig, Germany). The cells were grown 
in RPMI-1640 medium with 10  % fetal bovine serum, 
100 units/ml penicillin and 100  µg/ml streptomycin 
(Sigma, St Louis, MO) and kept at standard cell culture 
conditions.
Chemicals and antibodies
1,25D was purchased from Cayman Europe (Tallinn, 
Estonia), ATRA and curcumin were from Sigma. The 
compounds were dissolved in an absolute ethanol to 
1000  ×  final concentrations, and subsequently diluted 
in the culture medium to the required concentration. 
IFNα (cat. no. 11343506), IFNγ (cat. no. 11343536) and 
antibodies CD11b-FITC (cat. no. 21279113) and CD14-
PE (cat. no. 21270144), as well as appropriately labeled 
isotype controls were from ImmunoTools (Friesoythe, 
Germany). Mouse monoclonal anti-VDR (sc-13133), 
anti-Stat1 p84/p91 (sc-464) and anti-p-STAT1 (sc-8394), 
rabbit polyclonal anti-actin (sc-1616), anti-HDAC1 (sc-
7872) and anti-Histone H1 (sc-10806) were from Santa 
Cruz Biotechnology Inc. (Santa Cruz Biotechnology Inc., 
CA). Goat anti-rabbit IgG, anti-mouse IgG conjugated to 
peroxidase, anti-mouse conjugated to biotin and strepta-
vidin conjugated to peroxidase were from Jackson Immu-
noResearch (West Grove, PA).
Transfection reagents and procedure
Electrotransfection by Neon® Transfection System (Inv-
itrogen™, Carlsbad, CA) was performed as before [22] 
using control shRNA plasmid-A (sc-108060) or RARA 
shRNA plasmid (sc-29465-SH; both Santa Cruz). In order 
to obtain additional control cells, KG1 cells were seeded 
on 24-well plates (2 × 104 cells per well) and after 24 h 
the cells were infected with 20  μl of lentiviral particles 
containing scrambled shRNA sequences (sc-108080; 
Santa Cruz) in medium containing 1  μg/ml polybrene 
(Santa Cruz) for 8 h. The medium was changed and the 
cells were grown for 2 more days. After transfection the 
cells were grown in a medium supplemented with 1 µg/
ml puromycin (Santa Cruz). Medium and selective anti-
biotic were changed every 2  days and puromycin non-
resistant cells were cleared from the culture.
Flow cytometry
The expression of cell surface markers of differentiation 
was determined by flow cytometry. The cells were incu-
bated with 1,25D  ±  IFNs or curcumin for 96  h, then 
washed and stained with 1  µl of fluorescently labeled 
antibody (or the appropriate control immunoglobulins) 
for 1 h on ice. Next, they were washed with ice-cold PBS 
and suspended in 0.5 ml of PBS supplemented with 0.1 % 
BSA prior to analysis on FACS Calibur flow cytometer 
(Becton–Dickinson, San Jose, CA). Experiments were 
repeated at least three times. The acquisition parameters 
were set for an isotype control. Data analysis was per-
formed with use of WinMDI 2.8 software (freeware by 
Joseph Trotter).
Real‑time PCR
Isolation of total RNA, reverse transcription into cDNA 
and Real-time PCR reactions were performed as pub-
lished before [14], using CFX Real-time PCR System 
(Bio-Rad Laboratories Inc., CA). The sequences of VDR 
and GAPDH primers together with reaction conditions 
were described previously [37]. The FOP2–FGFR1, FOP2 
and FGFR1 primers were as published before [2]. The 
interferon response was evaluated by IFNr qRT-Primers 
(Invivogen) which allow to quantify the mRNA expres-
sion of well characterized IFN-induced genes: IFNB, 
OAS1, MX1, G1P2, IFIT1. Relative quantification (RQ) of 
gene expression was analyzed with ∆∆Cq method using 
GAPDH as the endogenous control. Experiments were 
repeated at least three times.
Western blotting
In order to prepare cytosolic, nucleosolic and chromatin 
fractions 5 × 106 cells/sample (equivalent of 15 μl packed 
cell volume) were washed with PBS and lysed using either 
Pierce Subcellular Protein Fractionation Kit or NE-PER 
Nuclear and Cytoplasmic Extraction Reagents (both from 
Thermo Fisher Scientific Inc., Worcester, MA) according 
to the user’s manual. Obtained lysates were denatured by 
adding 5× sample buffer and boiling for 5 min. For west-
ern blotting 25 μl of lysates were separated on 10 % SDS-
PAGE gels and transferred to PVDF membranes. The 
membranes were then dried, and incubated sequentially 
with primary (3  h) and a horseradish peroxidase-conju-
gated secondary antibody (1 h) at room temperature. In 
case of STAT1 detection biotin-conjugated secondary 
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antibody and peroxidase-conjugated streptavidin were 
used. The protein bands were visualized with a chemi-
luminescence (Santa Cruz). Then the membranes were 
stripped, dried again and probed with subsequent anti-
bodies. These experiments were repeated 2–5 times.
Chromatin analysis
Digestion of chromatin was carried out using EpiQ 
chromatin Analysis Kit according to manufacturer’s 
guidelines (Bio-Rad). All cells were viable and actively 
growing in culture at the time of experiment, approxi-
mately 2.5 ×  105 cells per sample were harvested. Cells 
were pelleted and resuspended in 100  µl of chromatin 
buffer. Digested (D) samples were treated with 2  µl of 
EpiQ nuclease, undigested (U) samples were not treated 
with nuclease. Both D and U samples were incubated at 
37  °C for 1 h. Stop buffer was added to the samples for 
10  min at 37  °C to stop chromatin digestion and there-
after the genomic DNA was extracted and purified, 
chromatin accessibility was then assessed by real-time 
quantitative PCR using CFX Real-time PCR system. For 
each cell type three digested samples and three undi-
gested samples were analyzed using EpiQ chromatin 
Kit Data Analysis Tool (http://www.bio-rad.com/epiq) 
and normalized against the RHO (Rhodopsin) gene as 
a negative reference to a closed chromatin structure. 
The GAPDH gene was a positive reference to an open 
chromatin structure. Primers to analyze the proximal 
promoter of the human VDR gene were designed as rec-
ommended by the manufacturer using Primer3 software. 
The sequences for VDR were forward: 5′-GGCTGAA-
GCGGGTATCCGCACCTAT-3′, and reverse: 5′-TTT-
GACAAGCAGAGACAGCCCAGCA-3′. Experiments 
were repeated three times.
PCR reaction
Genomic DNA from 5  ×  106 of cells was iso-
lated using GenElute™ Mammalian Genomic DNA 
Miniprep Kit (Sigma). FOP2 forward (AGATGAT 
CCGGGTATAATAA) and FGFR1 reverse (AGAA-
GAACCCCAGAGTTCAT) primers were used to amplify 
the ~ 5 kb genomic fusion sequence [28]. A PCR reaction 
was performed with 1 μl of Marathon DNA polymerase 
(A&A Biotechnology, Gdansk, Poland), 250  μM of each 
dNTP, 200  ng of each primer and 500  ng of genomic 
DNA in 50  μl of reaction mixture. The PCR reaction 
conditions were according to the polymerase protocol 
with annealing temperature of 53 °C, 5 min of elongation 
step and with 35 cycles. PCR products were visualized 
on a 1 % agarose gel stained with ethidium bromide and 
HyperLadder™ 1 kb and 25 bp (Bioline, London, UK).
Statistical analysis
The Student’s t test for independent samples was used 
to analyze the results obtained in experiments (Excel, 
Microsoft Office).
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